Amyloidogenic Potential of Transthyretin Variants

Human transthyretin (TTR) is an amyloidogenic protein whose mild amyloidogenicity is enhanced by many point mutations affecting considerably the amyloid disease phenotype. To ascertain whether the high amyloidogenic potential of TTR variants may be explained on the basis of the conformational change hypothesis, an aim of this work was to determine structural alterations for five amyloidogenic TTR variants crystallized under native and/or destabilizing (moderately acidic pH) conditions. While at acidic pH structural changes may be more significant because of a higher local protein flexibility, only limited alterations, possibly representing early events associated with protein destabilization, are generally induced by mutations. This study was also aimed at establishing to what extent wild-type TTR and its amyloidogenic variants are intrinsically prone to β-aggregation. We report the results of a computational analysis predicting that wild-type TTR possesses a very high intrinsic β-aggregation propensity which is on average not enhanced by amyloidogenic mutations. However, when located in β-strands, most of these mutations are predicted to destabilize the native β-structure. The analysis also shows that rat and murine TTR have a lower intrinsic β-aggregation propensity and a similar native β-structure stability compared with human TTR. This result is consistent with the lack of in vitro amyloidogenicity found for both murine and rat TTR. Collectively, the results of this study support the notion that the high amyloidogenic potential of human pathogenic TTR variants is determined by the destabilization of their native structures, rather than by a higher intrinsic β-aggregation propensity.

[1]  Randy J Read,et al.  Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Translation Functions Biological Crystallography Likelihood-enhanced Fast Translation Functions , 2022 .

[2]  D. Wemmer,et al.  A glimpse of a possible amyloidogenic intermediate of transthyretin , 2000, Nature Structural Biology.

[3]  H. M. Petrassi,et al.  An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. , 2001, Biochemistry.

[4]  Flavio Seno,et al.  Aggregation of natively folded proteins: a theoretical approach , 2007 .

[5]  P. Evans,et al.  Scaling and assessment of data quality. , 2006, Acta crystallographica. Section D, Biological crystallography.

[6]  L. Serrano,et al.  Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins , 2004, Nature Biotechnology.

[7]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[8]  S. Ventura,et al.  Recent structural and computational insights into conformational diseases. , 2008, Current medicinal chemistry.

[9]  R. Samudrala,et al.  An all-atom distance-dependent conditional probability discriminatory function for protein structure prediction. , 1998, Journal of molecular biology.

[10]  J. Kelly,et al.  Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.

[11]  J. Kelly,et al.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. , 1996, Biochemistry.

[12]  L. Cendron,et al.  Structural and mutational analyses of protein–protein interactions between transthyretin and retinol‐binding protein , 2008, The FEBS journal.

[13]  James C Sacchettini,et al.  Structural insight into pH-induced conformational changes within the native human transthyretin tetramer. , 2008, Journal of molecular biology.

[14]  A. Wojtczak,et al.  Structure of rat transthyretin (rTTR) complex with thyroxine at 2.5 A resolution: first non-biased insight into thyroxine binding reveals different hormone orientation in two binding sites. , 2001, Acta crystallographica. Section D, Biological crystallography.

[15]  J. Kelly,et al.  Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. , 2008, Biochemistry.

[16]  Joleen T White,et al.  D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? , 2003, Biochemistry.

[17]  M. Benson,et al.  The molecular biology and clinical features of amyloid neuropathy , 2007, Muscle & nerve.

[18]  G. Sheldrick,et al.  SHELXL: high-resolution refinement. , 1997, Methods in enzymology.

[19]  A Coda,et al.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. , 1995, Science.

[20]  L. Cendron,et al.  Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin. , 2007, Journal of molecular biology.

[21]  M. Newcomer,et al.  The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. , 1999, Biochemistry.

[22]  Structure of the Val122Ile variant transthyretin - a cardiomyopathic mutant. , 1996, Acta crystallographica. Section D, Biological crystallography.

[23]  C. Dobson,et al.  Protein misfolding, functional amyloid, and human disease. , 2006, Annual review of biochemistry.

[24]  J. Kelly,et al.  Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. , 1995, Biochemistry.

[25]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[26]  C. Dobson,et al.  Rationalization of the effects of mutations on peptide andprotein aggregation rates , 2003, Nature.

[27]  Silvio C. E. Tosatto,et al.  The PASTA server for protein aggregation prediction. , 2007, Protein engineering, design & selection : PEDS.

[28]  Michele Vendruscolo,et al.  Prediction of aggregation-prone regions in structured proteins. , 2008, Journal of molecular biology.

[29]  C. Dobson,et al.  In the Footsteps of Alchemists , 2004, Science.

[30]  F. Salvi,et al.  Genetic microheterogeneity of human transthyretin detected by IEF , 2007, Electrophoresis.

[31]  Flavio Seno,et al.  Common attributes of native-state structures of proteins, disordered proteins, and amyloid. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Heather T. McFarlane,et al.  Atomic structures of amyloid cross-β spines reveal varied steric zippers , 2007, Nature.

[34]  K. Sletten,et al.  Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  S J Oatley,et al.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. , 1977, Journal of molecular biology.

[36]  J. Kelly,et al.  Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. , 1992, Biochemistry.

[37]  Fabrizio Chiti,et al.  Amyloid formation by globular proteins under native conditions. , 2009, Nature chemical biology.

[38]  J. Hamilton,et al.  The X-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30→Met variant to 1.7-Å resolution , 1993 .

[39]  A G Leslie,et al.  Biological Crystallography Integration of Macromolecular Diffraction Data , 2022 .

[40]  J. Kelly,et al.  Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease. , 2003, Journal of molecular biology.

[41]  V. Shnyrov,et al.  Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin. , 2000, Biophysical chemistry.

[42]  Flavio Seno,et al.  Insight into the Structure of Amyloid Fibrils from the Analysis of Globular Proteins , 2006, PLoS Comput. Biol..

[43]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[44]  Meital Reches,et al.  Amyloid Fibril Formation by Pentapeptide and Tetrapeptide Fragments of Human Calcitonin* , 2002, The Journal of Biological Chemistry.

[45]  Y. Sakaki,et al.  'In vitro' amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants. , 1996, Biochimica et biophysica acta.

[46]  M. Saraiva,et al.  Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution. , 2001, Journal of molecular biology.

[47]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[48]  X-ray crystallographic studies of two transthyretin variants: further insights into amyloidogenesis. , 2005, Acta crystallographica. Section D, Biological crystallography.

[49]  A. Wojtczak Crystal structure of rat transthyretin at 2.5 A resolution: first report on a unique tetrameric structure. , 1997, Acta biochimica Polonica.

[50]  M. Saraiva,et al.  The Crystal Structure of Amyloidogenic Leu55→ Pro Transthyretin Variant Reveals a Possible Pathway for Transthyretin Polymerization into Amyloid Fibrils* , 1998, The Journal of Biological Chemistry.

[51]  N. Schormann,et al.  Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[52]  Rui M. M. Brito,et al.  Tetramer Dissociation and Monomer Partial Unfolding Precedes Protofibril Formation in Amyloidogenic Transthyretin Variants* , 2001, The Journal of Biological Chemistry.

[53]  Steven M. Johnson,et al.  Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. , 2005, Accounts of chemical research.

[54]  J. Kelly,et al.  Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. , 1993, Biochemistry.

[55]  M. Saraiva,et al.  The Tetrameric Protein Transthyretin Dissociates to a Non-native Monomer in Solution , 1999, The Journal of Biological Chemistry.

[56]  I. Wilson,et al.  Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. , 2005, Journal of molecular biology.

[57]  Michele Vendruscolo,et al.  Systematic In Vivo Analysis of the Intrinsic Determinants of Amyloid β Pathogenicity , 2007, PLoS biology.

[58]  A. Olofsson,et al.  A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. , 2000, Journal of molecular biology.

[59]  Joleen T White,et al.  Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. , 2004, Biochemistry.

[60]  J. Kelly,et al.  Human-Murine Transthyretin Heterotetramers Are Kinetically Stable and Non-amyloidogenic , 2008, Journal of Biological Chemistry.

[61]  D. Jenne,et al.  A new isoleucine substitution of Val-20 in transthyretin tetramers selectively impairs dimer-dimer contacts and causes systemic amyloidosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Brito,et al.  The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution , 1997, FEBS letters.

[63]  K. Kamide,et al.  Amyloid formation in rat transthyretin: effect of oxidative stress. , 2002, Clinica chimica acta; international journal of clinical chemistry.